EGFR and neoplasm: For example, in the antibody described by Tapia-Galisteo and colleagues, a CD3-specific single-chain variable fragment (scFv) was flanked by two different tumour-targeting VHH antibody fragments directed against epidermal growth factor receptor (EGFR) and EpCAM for the treatment of colorectal cancer (61).